# Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

> **NCT04460508** · PHASE2 · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 170 (estimated)

## Conditions studied

- Chemotherapy-induced Neutropenia
- Lymphoma

## Interventions

- **DRUG:** Pegylated rhG-CSF
- **DRUG:** rhG-CSF

## Key facts

- **NCT ID:** NCT04460508
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-20
- **Primary completion:** 2022-12-20
- **Final completion:** 2023-03-20
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460508, "Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04460508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*